PATIENT REPORTED MEASURES OF DEPRESSIVE SYMPTOMS AND FATIGUE IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

Authors
Category Primary study
JournalVALUE IN HEALTH
Year 2018
This article has no abstract
Epistemonikos ID: 23b0210bf6c372be02849d96860841fd22c4b232
First added on: Feb 09, 2025